Skip to content
Biodatica
Start free

Allogene Therapeutics

Buffalo, New York

OncologyCAR-TPhase IIListed · ALLO

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase II trial registered: Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

2w agoTrial registeredJun 29, 2026Source filing (opens the source filing in a new tab)

Momentum

85no change

Momentum 85 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    Nov 13, 2025

    Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis · RECRUITING · sponsor: Allogene Therapeutics · A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

    ClinicalTrials.gov · NCT07085104 (opens the source filing in a new tab)

  2. Trial

    Study registered

    Jan 31, 2025

    Hematologic Malignancies, Solid Tumors · ENROLLING_BY_INVITATION · sponsor: Allogene Therapeutics · Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product

    ClinicalTrials.gov · NCT06925685 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Jun 18, 2024

    Large B-cell Lymphoma · RECRUITING · sponsor: Allogene Therapeutics · Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

    ClinicalTrials.gov · NCT06500273 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources